drugset / Trial / NCT02946684
Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment
Phase 2/3
Completed
129 enrolled
Sven O. Skouby
Copenhagen University Hospital, Denmark · collabHolbaek Sygehus · collabHvidovre University Hospital · collabRegion Capital Denmark · collabRigshospitalet, Denmark · collabZealand University Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This project seeks to determine whether estradiol suppression achieved with adjuvant treatment with an aromatase inhibitor improves end-follicular and midluteal phase parameters during IVF. 128 patients will be randomized to either placebo or active treatment.
Timeline
- Start
- 2017-02-01
- Primary completion
- 2018-10-30
- Completion
- 2018-10-30
Publications
- Bulow NS, Warzecha AK, Nielsen MV, Andersen CY, Holt MD, Petersen MR, Sopa N, Zedeler A, Englund AL, Pinborg A, Grondahl ML, Skouby SO, Macklon NS. Impact of letrozole co-treatment during ovarian stimulation on oocyte yield, embryo development, and live birth rate in women with normal ovarian reserve: secondary outcomes from the RIOT trial. Hum Reprod. 2023 Nov 2;38(11):2154-2165. doi: 10.1093/humrep/dead182.
- Bulow NS, Skouby SO, Warzecha AK, Udengaard H, Andersen CY, Holt MD, Grondahl ML, Nyboe Andersen A, Sopa N, Mikkelsen ALE, Pinborg A, Macklon NS. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial. Hum Reprod. 2022 Jan 28;37(2):309-321. doi: 10.1093/humrep/deab249.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Letrozole | Other / unclassified | 5 mg | — |